Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 300 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 21.5
- Book Value ₹
- Dividend Yield %
- ROCE 62.0 %
- ROE 64.0 %
- Face Value ₹ 10.0
Pros
Cons
- Working capital days have increased from 62.2 days to 98.6 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 87 | 131 | 132 | |
| 80 | 120 | 112 | |
| Operating Profit | 7 | 11 | 20 |
| OPM % | 8% | 9% | 15% |
| 0 | 0 | 1 | |
| Interest | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 7 | 11 | 19 |
| Tax % | 26% | 28% | 28% |
| 5 | 8 | 14 | |
| EPS in Rs | 40.46 | 58.73 | 102.73 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 75% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 64% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 1 | 1 | 1 |
| Reserves | 5 | 13 | 27 |
| 2 | 11 | 12 | |
| 17 | 15 | 13 | |
| Total Liabilities | 26 | 40 | 54 |
| 1 | 6 | 5 | |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| 25 | 35 | 49 | |
| Total Assets | 26 | 40 | 54 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| -0 | 5 | 1 | |
| -1 | -5 | -0 | |
| 1 | 1 | -1 | |
| Net Cash Flow | -0 | 0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 81 | 62 | 88 |
| Inventory Days | 10 | 25 | 27 |
| Days Payable | 65 | 37 | 34 |
| Cash Conversion Cycle | 25 | 50 | 81 |
| Working Capital Days | 32 | 56 | 99 |
| ROCE % | 67% | 62% |
Documents
Announcements
No data available.
Annual reports
No data available.
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.